Correction to: Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal

Review Group ◽

Anaplastic Lymphoma ◽

Group Evaluation ◽

Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal

PharmacoEconomics ◽

10.1007/s40273-018-0720-8 ◽

2018 ◽

Vol 37 (5) ◽

pp. 645-654 ◽

Cited By ~ 1

Author(s):

Lindsay Claxton ◽

Joanne O’Connor ◽

Nerys Woolacott ◽

Kath Wright ◽

Robert Hodgson

Keyword(s):

Lung Cancer ◽

Evidence Review Group ◽

Small Cell ◽

Technology Appraisal ◽

Small Cell Lung ◽

Review Group ◽

Anaplastic Lymphoma ◽

Group Evaluation ◽

Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

PharmacoEconomics ◽

10.1007/s40273-017-0497-1 ◽

2017 ◽

Vol 35 (9) ◽

pp. 909-919 ◽

Cited By ~ 3

Author(s):

Philip Morgan ◽

Nerys Woolacott ◽

Mousumi Biswas ◽

Teumzghi Mebrahtu ◽

Melissa Harden ◽

...

Keyword(s):

Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Evidence Review Group ◽

Small Cell ◽

Technology Appraisal ◽

Small Cell Lung ◽

Review Group ◽

Anaplastic Lymphoma ◽

Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

PharmacoEconomics ◽

10.1007/s40273-019-00870-w ◽

2019 ◽

Vol 38 (4) ◽

pp. 317-324 ◽

Author(s):

Willem J. A. Witlox ◽

Antoinette D. I. van Asselt ◽

Robert Wolff ◽

Nigel Armstrong ◽

Gill Worthy ◽

...

Keyword(s):

Lung Cancer ◽

Locally Advanced ◽

Evidence Review Group ◽

Small Cell ◽

Technology Appraisal ◽

Small Cell Lung ◽

Review Group ◽

Unresectable Stage ◽

The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal

PharmacoEconomics ◽

10.1007/s40273-019-00779-4 ◽

2019 ◽

Vol 37 (9) ◽

pp. 1081-1091 ◽

Author(s):

Edward Cox ◽

Ros Wade ◽

Mathilde Peron ◽

Kristina Charlotte Dietz ◽

Alison Eastwood ◽

...

Keyword(s):

Cost Effectiveness ◽

Acute Lymphoblastic Leukaemia ◽

Lymphoblastic Leukaemia ◽

Evidence Review Group ◽

Technology Appraisal ◽

Inotuzumab Ozogamicin ◽

Review Group ◽

Group Evaluation ◽

Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal

PharmacoEconomics ◽

10.1007/s40273-018-0661-2 ◽

2018 ◽

Vol 36 (11) ◽

pp. 1299-1308 ◽

Author(s):

Micah Rose ◽

Jonathan Shepherd ◽

Petra Harris ◽

Karen Pickett ◽

Joanne Lord

Keyword(s):

Secondary Hyperparathyroidism ◽

Evidence Review Group ◽

Technology Appraisal ◽

Review Group ◽

Group Evaluation ◽

Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal

PharmacoEconomics ◽

10.1007/s40273-018-0698-2 ◽

2018 ◽

Vol 37 (2) ◽

pp. 131-139 ◽

Cited By ~ 1

Author(s):

Ros Wade ◽

Alessandro Grosso ◽

Emily South ◽

Claire Rothery ◽

Pedro Saramago ◽

...

Keyword(s):

Plaque Psoriasis ◽

Evidence Review Group ◽

Technology Appraisal ◽

Review Group ◽

Severe Plaque Psoriasis ◽

Group Evaluation ◽

Vedolizumab for Treating Moderately to Severely Active Crohn’s Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

PharmacoEconomics ◽

10.1007/s40273-016-0436-6 ◽

2016 ◽

Vol 34 (12) ◽

pp. 1241-1253 ◽

Cited By ~ 5

Author(s):

Rachid Rafia ◽

Alison Scope ◽

Sue Harnan ◽

John W. Stevens ◽

Matt Stevenson ◽

...

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Evidence Review Group ◽

Technology Appraisal ◽

Review Group ◽

Prior Therapy ◽

Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective

PharmacoEconomics ◽

10.1007/s40273-015-0296-5 ◽

2015 ◽

Vol 33 (11) ◽

pp. 1187-1194 ◽

Cited By ~ 11

Author(s):

Emma L. Simpson ◽

Sarah Davis ◽

Praveen Thokala ◽

Penny R. Breeze ◽

Peter Bryden ◽

...

Keyword(s):

Prostate Cancer ◽

Evidence Review Group ◽

Technology Appraisal ◽

Review Group ◽

Fulvestrant for Untreated Hormone-Receptor Positive Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

PharmacoEconomics ◽

10.1007/s40273-018-0725-3 ◽

2018 ◽

Vol 37 (6) ◽

pp. 753-762

Author(s):

Joanna Picot ◽

Neelam Kalita ◽

Wendy Gaisford ◽

Petra Harris ◽

Oluchukwu Onyimadu ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Evidence Review Group ◽

Technology Appraisal ◽

Review Group ◽

Hormone Receptor Positive ◽

Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

PharmacoEconomics ◽

10.1007/s40273-018-0738-y ◽

2018 ◽

Vol 37 (7) ◽

pp. 887-894 ◽

Author(s):

Bram L. T. Ramaekers ◽

Rob Riemsma ◽

Sabine Grimm ◽

Debra Fayter ◽

Sohan Deshpande ◽

...

Keyword(s):

Arsenic Trioxide ◽

Acute Promyelocytic Leukaemia ◽

Evidence Review Group ◽

Promyelocytic Leukaemia ◽

Technology Appraisal ◽

Review Group ◽